NovoCure (NVCR) Competitors

Stevanato Group (NYSE:STVN) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, profitability and community ranking.

Does the MarketBeat Community favor STVN or NVCR?

NovoCure received 447 more outperform votes than Stevanato Group when rated by MarketBeat users. Likewise, 63.10% of users gave NovoCure an outperform vote while only 62.50% of users gave Stevanato Group an outperform vote.

Company	Underperform	Outperform
Stevanato Group	Outperform Votes 30 62.50%	Underperform Votes 18 37.50%
NovoCure	Outperform Votes 477 63.10%	Underperform Votes 279 36.90%

Does the media prefer STVN or NVCR?

In the previous week, NovoCure had 5 more articles in the media than Stevanato Group. MarketBeat recorded 11 mentions for NovoCure and 6 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 1.22 beat NovoCure's score of 0.53 indicating that Stevanato Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Is STVN or NVCR more profitable?

Stevanato Group has a net margin of 10.47% compared to NovoCure's net margin of -25.93%. Stevanato Group's return on equity of 9.86% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	10.47%	9.86%	5.79%
NovoCure	-25.93%	-41.48%	-12.74%

Do insiders and institutionals have more ownership in STVN or NVCR?

84.6% of NovoCure shares are held by institutional investors. 0.7% of Stevanato Group shares are held by insiders. Comparatively, 6.3% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has better valuation and earnings, STVN or NVCR?

Stevanato Group has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	$1.10B	6.05	$157.62M	$0.48	45.94
NovoCure	$605.22M	2.87	-$207.04M	-$1.56	-10.15

Which has more volatility & risk, STVN or NVCR?

Stevanato Group has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.

Do analysts rate STVN or NVCR?

NovoCure has a consensus price target of $34.17, suggesting a potential upside of 115.83%. Given NovoCure's higher probable upside, analysts plainly believe NovoCure is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
NovoCure	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Stevanato Group beats NovoCure on 11 of the 18 factors compared between the two stocks.